Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kiran J. Philip"'
Publikováno v:
Vascular Health and Risk Management, Vol 2010, Iss default, Pp 273-280 (2010)
Jeremy A Falk, Kiran J Philip, Ernst R SchwarzCedars Sinai Women’s Guild Lung Institute, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USAAbstract: Pulmonary hypertension (PH) is found in a vast array of diseases, with
Externí odkaz:
https://doaj.org/article/045a417005dc49a68cc5217ff87876de
Autor:
Keri L. Monda, Teresa N. Harrison, Kristi Reynolds, Lei Qian, Songyue Chen, Kiran J. Philip, Stephanie R. Reading, Jin-Wen Y Hsu, Katie Mues, Somjot S Brar
Publikováno v:
Circulation. 137
Background: Studies have demonstrated benefit of statin therapy in patients with peripheral artery disease (PAD). However, use of statins in patients with PAD has been found to be suboptimal. We examined trends in statin use and discontinuation among
Publikováno v:
Therapeutic Advances in Cardiovascular Disease. 7:260-273
The first case of noncompaction was described in 1932 after an autopsy performed on a newborn infant with aortic atresia/coronary–ventricular fistula. Isolated noncompaction cardiomyopathy was first described in 1984. A review on selected/relevant
Autor:
Kiran J. Philip, Lawrence S.C. Czer, Daniel Luthringer, Victor Y. Cheng, Ryan P. Morrissey, Jamal S. Rana, Ernst R. Schwarz, Robert M. Kass
Publikováno v:
Heart & Lung. 40:340-345
Giant-cell myocarditis is an autoimmune myocarditis that rapidly progresses to heart failure, and is often associated ventricular tachycardia. We describe an otherwise healthy patient who was acutely ill with decompensated heart failure and ventricul
Publikováno v:
Journal of Cardiovascular Medicine. 11:919-927
Heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with over 290 000 deaths in the United States each year. This article reviews palliative care and self-care, which
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 16:14-23
Heart failure (HF) is a complex progressive multisystem disease state with significant morbidity and mortality, which is not solely defined by pathology of the cardiovascular system but also is influenced by neurohormonal regulatory adjustments, peri
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 15:231-243
Recent advances in heart failure therapy include a variety of mechanical and device-based technologies that target structural aspects of heart failure that cannot be treated with drug therapy alone; these newer therapies can collectively be described
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 15:102-111
Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy
Publikováno v:
Vascular Health and Risk Management, Vol 2010, Iss default, Pp 273-280 (2010)
Vascular Health and Risk Management
Vascular Health and Risk Management
Jeremy A Falk, Kiran J Philip, Ernst R SchwarzCedars Sinai Women’s Guild Lung Institute, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USAAbstract: Pulmonary hypertension (PH) is found in a vast array of diseases, with
Autor:
Lawrence S.C. Czer, Kiran J. Philip, Alfredo Trento, Laurent Cleenewerck, Sinan Simsir, Stuart G. Finder, Ernst R. Schwarz
Publikováno v:
Journal of Religion and Health
Deciding who should receive maximal technological treatment options and who should not represents an ethical, moral, psychological and medico-legal challenge for health care providers. Especially in patients with chronic heart failure, the ethical an